文献速递淋巴瘤造血干细胞移植与细胞治疗

阿基仑赛治疗大B细胞淋巴瘤的种族与民族真实世界及临床试验结局

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.
PubMed 文献 · Blood · 2024-01-01

该研究基于国际血液与骨髓移植研究中心数据库的1290例真实世界患者及ZUMA-1和ZUMA-7试验的106例和169例患者,分析阿基仑赛治疗复发/难治性大B细胞淋巴瘤的结局。总生存期在各组间一致,但非西班牙裔黑人患者的总缓解率和完全缓解率低于非西班牙裔白人,无进展生存期更短,非西班牙裔亚洲患者缓解持续时间更长。

要点

  • 非西班牙裔黑人患者总缓解率(OR 0.37,95%CI 0.22-0.63)和完全缓解率(OR 0.57,95%CI 0.33-0.97)低于非西班牙裔白人。
  • 非西班牙裔黑人患者无进展生存期较非西班牙裔白人(HR 1.41,95%CI 1.04-1.90)和非西班牙裔亚洲人(HR 1.67,95%CI 1.08-2.59)更短。
  • 非西班牙裔亚洲患者缓解持续时间长于非西班牙裔白人(HR 0.56,95%CI 0.33-0.94)和西班牙裔患者(HR 0.54,95%CI 0.30-0.97)。

核心结论

  • 真实世界和临床试验中,阿基仑赛治疗复发/难治性大B细胞淋巴瘤的总生存期在种族/民族组间一致,但缓解率和无进展生存期存在差异。

研究设计与样本

  • 真实世界研究纳入2017年至2020年间接受阿基仑赛的1290例患者,数据来自国际血液与骨髓移植研究中心数据库;临床试验纳入ZUMA-1的106例和ZUMA-7的169例患者。

主要发现

  • 非西班牙裔黑人患者总缓解率低于非西班牙裔白人(OR 0.37,95%CI 0.22-0.63),完全缓解率也较低(OR 0.57,95%CI 0.33-0.97)。
  • 非西班牙裔黑人患者无进展生存期较非西班牙裔白人缩短(HR 1.41,95%CI 1.04-1.90),较非西班牙裔亚洲人也缩短(HR 1.67,95%CI 1.08-2.59)。
  • 非西班牙裔亚洲患者缓解持续时间长于非西班牙裔白人(HR 0.56,95%CI 0.33-0.94)和西班牙裔患者(HR 0.54,95%CI 0.30-0.97)。
  • 细胞因子释放综合征发生率在各组间无差异,但非西班牙裔白人患者任何级别免疫效应细胞相关神经毒性综合征发生率高于其他患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting its use, outcomes stratified by race and ethnicity groups are limited. Here, we report clinical outcomes with axi-cel in patients with R/R LBCL by race and ethnicity in both real-world and clinical trial settings. In the real-world setting, 1290 patients who received axi-cel between 2017 and 2020 were identified from the Center for International Blood and Marrow Transplant Research database; 106 and 169 patients were included from the ZUMA-1 and ZUMA-7 trials, respectively. Overall survival was consistent across race/ethnicity groups. However, non-Hispanic (NH) Black patients had lower overall response rate (OR, 0.37; 95% CI, 0.22-0.63) and lower complete response rate (OR, 0.57; 95% CI, 0.33-0.97) than NH White patients. NH Black patients also had a shorter progression-free survival vs NH White (HR, 1.41; 95% CI, 1.04-1.90) and NH Asian patients (HR, 1.67; 95% CI, 1.08-2.59). NH Asian patients had a longer duration of response than NH White (HR, 0.56; 95% CI, 0.33-0.94) and Hispanic patients (HR, 0.54; 95% CI, 0.30-0.97). There was no difference in cytokine release syndrome by race/ethnicity; however, higher rates of any-grade immune effector cell-associated neurotoxicity syndrome were observed in NH White patients than in other patients. These results provide important context when treating patients with R/R LBCL with CAR T-cell therapy across different racial and ethnic groups. ZUMA-1 and ZUMA-7 (ClinicalTrials.gov identifiers: #NCT02348216 and #NCT03391466, respectively) are registered on ClinicalTrials.gov.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Locke FL, Siddiqi T, Jacobson CA, et al. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood. 2024. PMID: 38635762. doi:10.1182/blood.2023023447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。